On October 20, 2020 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology and neuroscience, reported the presentation of new preclinical data on its VISTA antagonist antibodies at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Special Conference on Tumor Immunology and Immunotherapy (Press release, Kineta, OCT 20, 2020, View Source;utm_medium=rss&utm_campaign=kineta-presents-new-preclinical-data-on-its-vista-antagonist-antibodies-at-the-american-association-for-cancer-research-virtual-special-conference-on-tumor-immunology-and-immunotherapy [SID1234568673]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Thierry Guillaudeux, PhD, Vice President Immuno-oncology at Kineta, presented the new preclinical data on the company’s fully human anti-VISTA antibodies during the Innate and Adaptive Checkpoints plenary session. Key findings from the presentation include the following:
Kineta’s anti-VISTA antibodies carry unique sequences and the selected lead candidates exhibit potencies in the subnanomolar range
Kineta’s human anti-VISTA antibodies are highly specific and cross-react with cyno-VISTA but not mouse-VISTA
VISTA antagonist antibody induces strong anti-tumor response as a single agent or in combo-therapies with anti-PD-L1 or anti-CTLA-4 in CT26 tumor models
VISTA antagonist antibody activates dendritic cells in the blood and reduces MDSCs
"We are very pleased with the development of our new anti-VISTA antibody program and the selection of our lead candidates" said Thierry Guillaudeux. "VISTA is a unique immuno-oncology target for the treatment of non-immunogenic tumors, with a central role in re-programming the tumor microenvironment to turn cold tumors hot."
VISTA is a key driver of the immunosuppressive tumor microenvironment (TME) and is overexpressed on myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs). It is a critical myeloid cell immune-checkpoint, and VISTA blockade can reprogram suppressive myeloid cells and reactivate antitumor immune function. Blocking VISTA activates an immune cell cascade that increases T cell effector functions to drive an efficient anti-tumor response. Preclinical studies have demonstrated single agent anti-VISTA activity but also demonstrate that targeting VISTA in combination with PD-1, PD-L1 or CTLA-4 can significantly improve the efficacy of those checkpoint inhibitors.
Presentation Details:
Title: Highly potent fully human anti-VISTA antibodies – A new target checkpoint inhibitor against immunosuppressive myeloid cells
Session Title: Innate and Adaptive Checkpoints
Date/Time: October 19, 2020, 2:20 PM – 2:29 PM Eastern
Presenter: Thierry Guillaudeux, PhD